{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:18:44Z","timestamp":1792718324388,"version":"4.5.0"},"reference-count":94,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,28]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Elderly patients with rheumatoid arthritis (RA) are frequently associated with higher disease activity and impaired physical function, although they show intolerance for conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), such as methotrexate, because of their comorbidities. However, the present treatment recommendation based on randomized controlled trials is not distinguished by age or comorbidities. Therefore, this review aimed to investigate the efficacy and safety of biological DMARDs (bDMARDs) and Janus kinase inhibitors (JAKi) in elderly patients. Present bDMARDs, including tumor necrosis factor inhibitors (TNFi), cytotoxic T lymphocyte-associated antigen-4-immunoglobulin (abatacept), interleukin (IL)-6 receptor antibody (tocilizumab and salirumab), and anti-CD20 antibody (rituximab), may be similarly or slightly less effective or safe in elderly patients compared with younger patients. Oral glucocorticoid use, prolonged disease duration, and very old patients appear to be associated with an increased risk of adverse events, such as serious infection. Some recent cohort studies demonstrated that non-TNFi showed better retention than TNFi in elderly patients. Both TNFi and non-TNFi agents may not strongly influence the risk of adverse events such as cardiovascular events and malignancy in elderly patients. Regarding JAKi, the efficacy appears to be similar, although the safety (particularly for serious infections, including herpes zoster) may be attenuated by aging.<\/jats:p>","DOI":"10.1093\/mr\/roab003","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T14:03:32Z","timestamp":1639231412000},"page":"256-262","source":"Crossref","is-referenced-by-count":13,"title":["Drug efficacy and safety of biologics and Janus kinase inhibitors in elderly patients with rheumatoid arthritis"],"prefix":"10.1093","volume":"32","author":[{"given":"Kosuke","family":"Ebina","sequence":"first","affiliation":[{"name":"Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"2022030105113512200_R1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40266-016-0374-1","article-title":"Safety and efficacy of biological disease-modifying antirheumatic drugs in older rheumatoid arthritis patients: staying the distance","volume":"33","author":"Ishchenko","year":"2016","journal-title":"Drugs Aging"},{"key":"2022030105113512200_R2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/1756-185X.12998","article-title":"The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study","volume":"20","author":"Kato","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2022030105113512200_R3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/acr.22281","article-title":"Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis","volume":"66","author":"Curtis","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2022030105113512200_R4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3109\/03009741003604542","article-title":"Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA","volume":"39","author":"Nakajima","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"2022030105113512200_R5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.rdc.2006.12.011","article-title":"Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient","volume":"33","author":"Ranganath","year":"2007","journal-title":"Rheum Dis Clin North Am"},{"key":"2022030105113512200_R6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216624","article-title":"Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis\u2014the ANSWER cohort study","volume":"14","author":"Ebina","year":"2019","journal-title":"PLoS One"},{"key":"2022030105113512200_R7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022030105113512200_R8","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/j.1532-5415.2010.02965.x","article-title":"Rheumatoid arthritis: a role for immunosenescence?","volume":"58","author":"Lindstrom","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"2022030105113512200_R9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000164393","article-title":"Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease","volume":"55","author":"Chen","year":"2009","journal-title":"Gerontology"},{"key":"2022030105113512200_R10","article-title":"Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort","author":"Murata","journal-title":"Int J Rheum Dis"},{"key":"2022030105113512200_R11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/ket449","article-title":"Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort","volume":"53","author":"Arnold","year":"2014","journal-title":"Rheumatology"},{"key":"2022030105113512200_R12","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/ard.2005.051144","article-title":"Do patients with older-onset rheumatoid arthritis receive less aggressive treatment?","volume":"65","author":"Tutuncu","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2022030105113512200_R13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/acr.21812","article-title":"Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis","volume":"65","author":"Widdifield","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2022030105113512200_R14","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1136\/ard.2005.050377","article-title":"Patterns of cardiovascular risk in rheumatoid arthritis","volume":"65","author":"Solomon","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2022030105113512200_R15","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2022030105113512200_R16","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/acr.22510","article-title":"Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients","volume":"67","author":"Zhang","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2022030105113512200_R17","first-page":"1243","article-title":"Does age bias the aggressive treatment of elderly patients with rheumatoid arthritis?","volume":"32","author":"Harrison","year":"2005","journal-title":"J Rheumatol"},{"key":"2022030105113512200_R18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40268-015-0106-8","article-title":"Evaluation of the safety and effectiveness of add-on tacrolimus in patients with rheumatoid arthritis who failed to show an adequate response to biological DMARDs: the interim results of a specific drug use-results survey of tacrolimus","volume":"15","author":"Ishida","year":"2015","journal-title":"Drugs R D"},{"key":"2022030105113512200_R19","article-title":"The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab","author":"Ebina","journal-title":"Mod Rheumatol"},{"key":"2022030105113512200_R20","article-title":"Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: a retrospective study","author":"Yoshikawa","journal-title":"Mod Rheumatol"},{"key":"2022030105113512200_R21","doi-asserted-by":"crossref","first-page":"ii13","DOI":"10.1136\/ard.2004.028530","article-title":"Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues","volume":"63","author":"Wolfe","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2022030105113512200_R22","first-page":"234","article-title":"Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis","volume":"33","author":"Bathon","year":"2006","journal-title":"J Rheumatol"},{"key":"2022030105113512200_R23","article-title":"Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis\u2014the ANSWER cohort study","volume":"21","author":"Ebina","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022030105113512200_R24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194130","article-title":"Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis\u2014the ANSWER cohort study","volume":"13","author":"Ebina","year":"2018","journal-title":"PLoS One"},{"key":"2022030105113512200_R25","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1673-1","article-title":"Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study","volume":"20","author":"Hashimoto","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2022030105113512200_R26","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-021-05609-7","article-title":"Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study","author":"Ebina","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2022030105113512200_R27","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1007\/s10067-020-05015-5","article-title":"Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis\u2014the ANSWER cohort study","volume":"39","author":"Ebina","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2022030105113512200_R28","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02232-w","article-title":"Drug retention of 7 biologics and tofacitinib in biologics-naive and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study","volume":"22","author":"Ebina","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2022030105113512200_R29","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00296-020-04660-y","article-title":"Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study","volume":"40","author":"Jinno","year":"2020","journal-title":"Rheumatol Int"},{"key":"2022030105113512200_R30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","article-title":"Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"61","author":"Du Pan","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2022030105113512200_R31","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/acr.22788","article-title":"Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry","volume":"68","author":"Favalli","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2022030105113512200_R32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","article-title":"Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2022030105113512200_R33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","article-title":"Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab","volume":"74","author":"Neovius","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022030105113512200_R34","first-page":"523","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases","volume":"55","author":"Souto","year":"2016","journal-title":"Rheumatology"},{"key":"2022030105113512200_R35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40266-015-0341-2","article-title":"Targeting low disease activity in elderly-onset rheumatoid arthritis: current and future roles of biological disease-modifying antirheumatic drugs","volume":"33","author":"Sugihara","year":"2016","journal-title":"Drugs Aging"},{"key":"2022030105113512200_R36","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/rheumatology\/ket224","article-title":"Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis","volume":"52","author":"Ranganath","year":"2013","journal-title":"Rheumatology"},{"key":"2022030105113512200_R37","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/art.22688","article-title":"Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study","volume":"57","author":"Genevay","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2022030105113512200_R38","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1136\/ard.2008.094730","article-title":"Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis","volume":"68","author":"Radovits","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022030105113512200_R39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/acr.20372","article-title":"Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis","volume":"63","author":"Weinblatt","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2022030105113512200_R40","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/rheumatology\/kep291","article-title":"Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients","volume":"48","author":"Koller","year":"2009","journal-title":"Rheumatology"},{"key":"2022030105113512200_R41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40744-018-0095-5","article-title":"Real-world treatment patterns for golimumab and concomitant medications in Japanese rheumatoid arthritis patients","volume":"5","author":"Okazaki","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2022030105113512200_R42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00296-018-4205-z","article-title":"How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol","volume":"39","author":"Torrente-Segarra","year":"2019","journal-title":"Rheumatol Int"},{"key":"2022030105113512200_R43","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12016-009-8142-1","article-title":"Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study","volume":"38","author":"Filippini","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"2022030105113512200_R44","first-page":"22","article-title":"Rheumatoid arthritis in elderly patients","volume":"64","author":"Majithia","year":"2009","journal-title":"Geriatrics"},{"key":"2022030105113512200_R45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40801-018-0139-8","article-title":"Persistence with biological disease-modifying antirheumatic drugs and its associated resource utilization and costs","volume":"5","author":"Sruamsiri","year":"2018","journal-title":"Drugs Real World Outcomes"},{"key":"2022030105113512200_R46","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2022030105113512200_R47","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00002512-200724030-00005","article-title":"Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis","volume":"24","author":"Fleischmann","year":"2007","journal-title":"Drugs Aging"},{"key":"2022030105113512200_R48","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","article-title":"Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology"},{"key":"2022030105113512200_R49","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/pds.3238","article-title":"Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?","volume":"21","author":"Toh","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022030105113512200_R50","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.22600","article-title":"Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis","volume":"56","author":"Schneeweiss","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2022030105113512200_R51","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1086\/598331","article-title":"Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis","volume":"48","author":"McDonald","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2022030105113512200_R52","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/1756-185X.12348","article-title":"Risk factors of adverse events during treatment in elderly patients with rheumatoid arthritis: an observational study","volume":"20","author":"Iwanaga","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2022030105113512200_R53","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3899\/jrheum.140103","article-title":"Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-alpha (TNF-alpha) targeted biologics and recently licensed TNF-alpha inhibitors: data from clinical trials and national registries","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"2022030105113512200_R54","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/rheumatology\/keu172","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatology"},{"key":"2022030105113512200_R55","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000080","article-title":"Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis","volume":"1","author":"Nurmohamed","year":"2015","journal-title":"RMD Open"},{"key":"2022030105113512200_R56","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1136\/annrheumdis-2015-207870","article-title":"Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis","volume":"75","author":"Zhang","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022030105113512200_R57","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ijcard.2012.12.085","article-title":"T-cell co-stimulation by CD28-CD80\/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development","volume":"168","author":"Ewing","year":"2013","journal-title":"Int J Cardiol"},{"key":"2022030105113512200_R58","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ahj.2008.02.025","article-title":"Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis","volume":"156","author":"Setoguchi","year":"2008","journal-title":"Am Heart J"},{"key":"2022030105113512200_R59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022030105113512200_R60","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000314","article-title":"Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA","volume":"3","author":"Jani","year":"2017","journal-title":"RMD Open"},{"key":"2022030105113512200_R61","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/rheumatology\/kev437","article-title":"Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology\u2019s ORA registry","volume":"55","author":"Lahaye","year":"2016","journal-title":"Rheumatology"},{"key":"2022030105113512200_R62","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3899\/jrheum.160051","article-title":"Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naive rheumatoid arthritis: results from the ABROAD study","volume":"43","author":"Sekiguchi","year":"2016","journal-title":"J Rheumatol"},{"key":"2022030105113512200_R63","article-title":"Risk of hospitalized infection and initiation of abatacept versus TNF inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study","author":"Chen","journal-title":"Arthritis Care Res"},{"key":"2022030105113512200_R64","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/art.39399","article-title":"Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022030105113512200_R65","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7678542","article-title":"Lack of proinflammatory cytokine interleukin-6 or tumor necrosis factor receptor-1 results in a failure of the innate immune response after bacterial meningitis","volume":"2016","author":"Albrecht","year":"2016","journal-title":"Mediators Inflamm"},{"key":"2022030105113512200_R66","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/annrheumdis-2015-207362","article-title":"Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry","volume":"75","author":"Salmon","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022030105113512200_R67","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients","volume":"48","author":"Fernandez-Diaz","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2022030105113512200_R68","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/151626","article-title":"Anti-cyclic citrullinated peptide antibodies and severity of interstitial lung disease in women with rheumatoid arthritis","volume":"2015","author":"Rocha-Munoz","year":"2015","journal-title":"J Immunol Res"},{"key":"2022030105113512200_R69","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semarthrit.2016.09.011","article-title":"Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-a longitudinal analysis","volume":"46","author":"Wunderlich","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2022030105113512200_R70","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3899\/jrheum.120906","article-title":"Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program","volume":"40","author":"Weinblatt","year":"2013","journal-title":"J Rheumatol"},{"key":"2022030105113512200_R71","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/rheumatology\/kez604","article-title":"Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study","volume":"59","author":"De Germay","year":"2020","journal-title":"Rheumatology"},{"key":"2022030105113512200_R72","article-title":"Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients","volume":"17","author":"Migita","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2022030105113512200_R73","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/acr.21838","article-title":"Abatacept and reduced immune response to pandemic 2009 influenza A\/H1N1 vaccination in patients with rheumatoid arthritis","volume":"65","author":"Ribeiro","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2022030105113512200_R74","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2146\/ajhp070449","article-title":"Tocilizumab: the first interleukin-6-receptor inhibitor","volume":"65","author":"Sebba","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"2022030105113512200_R75","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/annrheumdis-2016-210297","article-title":"Low immunogenicity of tocilizumab in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022030105113512200_R76","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/s10165-010-0366-7","article-title":"Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)","volume":"21","author":"Yamanaka","year":"2011","journal-title":"Mod Rheumatol"},{"key":"2022030105113512200_R77","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jbspin.2014.07.010","article-title":"Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis","volume":"82","author":"Pers","year":"2015","journal-title":"Joint Bone Spine"},{"key":"2022030105113512200_R78","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2022030105113512200_R79","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.atherosclerosis.2013.04.031","article-title":"Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis","volume":"229","author":"Strang","year":"2013","journal-title":"Atherosclerosis"},{"key":"2022030105113512200_R80","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02233-9","article-title":"Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry","volume":"22","author":"Kawabe","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2022030105113512200_R81","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/rheumatology\/key361","article-title":"Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis","volume":"58","author":"Emery","year":"2019","journal-title":"Rheumatology"},{"key":"2022030105113512200_R82","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/acr2.11188","article-title":"Subcutaneous sarilumab in patients with rheumatoid arthritis who previously received subcutaneous sarilumab or intravenous tocilizumab: an open-label extension of a randomized clinical trial","volume":"2","author":"Emery","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2022030105113512200_R83","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02194-z","article-title":"Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies","volume":"22","author":"Genovese","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2022030105113512200_R84","doi-asserted-by":"crossref","DOI":"10.1186\/ar4521","article-title":"Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2484 patients","volume":"16","author":"Wendler","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2022030105113512200_R85","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/acr.22314","article-title":"Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry","volume":"66","author":"Payet","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2022030105113512200_R86","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"key":"2022030105113512200_R87","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000546","article-title":"Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"2022030105113512200_R88","first-page":"390","article-title":"Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis","volume":"35","author":"Curtis","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2022030105113512200_R89","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/acr.23769","article-title":"Risk for herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids","volume":"71","author":"Curtis","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2022030105113512200_R90","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/art.40911","article-title":"Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"71","author":"Charles-Schoeman","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022030105113512200_R91","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022030105113512200_R92","article-title":"A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years","author":"Takeuchi","journal-title":"Mod Rheumatol"},{"key":"2022030105113512200_R93","doi-asserted-by":"crossref","DOI":"10.1007\/s40744-021-00284-1","article-title":"Comparative efficacy and safety of peficitinib versus tofacitinib and baricitinib for treatment of rheumatoid arthritis: a systematic review and network meta-analysis","author":"Tanaka","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2022030105113512200_R94","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/acr2.11150","article-title":"Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center\u2019s experience with 400 patients","volume":"2","author":"Stevens","year":"2020","journal-title":"ACR Open Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roab003\/41745990\/roab003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/2\/256\/42644851\/roab003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/2\/256\/42644851\/roab003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T07:31:24Z","timestamp":1726299084000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/2\/256\/6348532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":94,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,8,12]]},"published-print":{"date-parts":[[2022,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roab003","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,8,12]]}}}